Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Other Non-Current Liabilities of $400000.0 for Q1 2026, down 90.98% year-over-year from $4.4 million in Q1 2025, and down 90.98% quarter-over-quarter from $4.4 million in Q1 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Other Non-Current Liabilities for 2 consecutive years, with $400000.0 the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2025 | 4.44 Mn |